Insulin glargine and glulisine SoloSTAR^®pens for the treatment of diabetes

Abstract

Insulin is an effective medication for lowering hemoglobin A(1c) values and can be used for both basal and prandial coverage of hyperglycemia in Type 1 and Type 2 diabetes. Despite its effectiveness there is still reluctance by patients and physicians to add insulin into the treatment regimen for Type 2 diabetes when needed. One of the key barriers to initiating insulin therapy is the method of delivery. Insulin delivery pens are continually developed as a means to improve upon the vial and syringe and to make it easier for patients to incorporate insulin therapy into their lifestyles. The SoloSTAR pen (Sanofi-Aventis, Paris, France) was developed to make insulin delivery easier and to help eliminate barriers to the initiation of insulin therapy. In this article, we discuss the features and characteristics of SoloSTAR that overcome existing unmet needs.

Comparison of Usability and Patient Preference for Insulin Pen Needles Produced with Different Production Techniques: “Thin-Wall” Needles Compared to “Regular-Wall” Needles: An Open-Label Study

“…[1][2][3][4] Many articles can be found in the literature considering the usage of different insulin pens relative to clinical experiences, patient acceptance and adherence, issues of education, healthcare costs, and reliability and accuracy of pens, [5][6][7][8][9][10][11] but there are only very few publications considering the corresponding pen needles, especially comparing pen needles. The only repeated needle issue is the potential number of recommended injections with one pen needle.…”

The role of insulin glulisine to improve glycemic control in children with diabetes mellitus

“…There was one published pharmacokinetic study, 22 three review articles, 23,24 and a recent abstract 25 detailing the safety and efficacy of lispro versus glulisine. Although the data are limited, the literature is in favor of the general efficacy of glulisine as a rapid-acting analog in …”

The role of insulin glulisine to improve glycemic control in children with diabetes mellitus

“…There was one published pharmacokinetic study,22 three review articles,23,24 and a recent abstract25 detailing the safety and efficacy of lispro versus glulisine. Although the data are limited, the literature is in favor of the general efficacy of glulisine as a rapid-acting analog in pediatric patients.…”